UNSPSC 51152105: Atropine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152105 Atropine/phenobarbital is a Commodity code that in practice covers pharmaceutical products and drug-intervention systems procured by state and local health agencies. Recent state and local opportunities tagged to this code show actual purchasing focused on naloxone (an opioid-reversal medication) and drug deactivation systems rather than atropine or phenobarbital specifically, signaling a disconnect between the nominal code scope and current market activity. State and local health departments and human services commissions are the primary issuing bodies, soliciting medications and related systems to support community health, opioid-response, and pharmacy benefit initiatives. The work involves product procurement through competitive bidding (IFB and RFI processes) with delivery and inventory management requirements, including quarterly fulfillment schedules, compliance with federal cross-cutting requirements when FEMA funding is involved, E-Verify and drug-free workplace certification, and standard insurance and bonding provisions.

Seminole County, Florida and the Texas Health and Human Services Commission represent recent activity in the Southeast and South. Seminole County issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health building, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs and negotiated net-pricing models outside traditional pharmacy benefit manager arrangements, an exploratory phase preceding formal RFP issuance. The source does not support activity in additional states or characterize the issuing-body mix beyond these two examples.